Dr Rajat Bannerji speaks to ecancer about the CAPTIVATE study.
It is a trial investigating a fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL.
Initially, he explains the background of the study. Dr Bannerji then discusses the methodology and results of the study.
He mentions that first-line I+V is an all-oral, once-daily, chemotherapy-free, fixed-duration regimen that provides deep, durable responses in patients with CLL/SLL, including those with genomic high-risk features.
CR, uMRD rates, PFS, and OS appear favourable.
In the end, he talks about the safety profile of I+V.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.